Sacubitril Valsartan Enhances Cardiac Function and Alleviates Myocardial Infarction in Rats through a SUV39H1/SPP1...

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Pharmacology

Background:

• Sacubitril valsartan (lcz696) is an alternative treatment for heart failure.
• Myocardial infarction (MI) leads to significant cardiac damage and heart failure.

Purpose of the Study:

• To investigate the effects of lcz696 on myocardial infarction (MI) in a rat model.
• To identify the molecular mechanisms underlying lcz696's protective effects in MI.

Main Methods:

• Induction of MI in rats via left anterior descending artery ligation, followed by lcz696 treatment.
• Analysis of the GSE47495 heart failure dataset and Gene Ontology (GO) enrichment analysis.
• Chromatin immunoprecipitation (ChIP) assays to assess SUV39H1 and H3K9me3 enrichment at the SPP1 promoter.

Main Results:

• Lcz696 treatment significantly reduced cardiac injury, improved cardiac function (left ventricular fractional shortening and ejection fraction), and decreased oxidative stress and inflammation.
• SUV39H1 expression was elevated, while SPP1 expression declined in cardiac tissues post-lcz696 treatment.
• SUV39H1-mediated H3K9me3 modification suppressed SPP1 expression; SUV39H1 silencing blocked lcz696's benefits, whereas SPP1 silencing alleviated injury.

Conclusions:

• Lcz696 enhances cardiac function and alleviates myocardial infarction in rats.
• The protective effects of lcz696 are mediated through the SUV39H1/SPP1 axis, involving SUV39H1-catalyzed H3K9me3 modification to suppress SPP1 expression.